| Identification | More | [Name]
Lercanidipine hydrochloride | [CAS]
132866-11-6 | [Synonyms]
75
CLAP
mE10
c-E10
CIPER
BCL10
CarMen
LerzaM
Zandip
Lercan
Zanicor
Corifeo
Renovia
Vasodip
Lercadip
Lercapin
Lercaton
LerkaMen
Cardiovasc
BCL-10 human
Lercaridipine
LERCANIDIPINE HCL
B-cell CLL/lymphoma 10
B-cell lymphoma/leukemia 10
LERCANIDIPINE HYDROCHLORIDE
LERCANIDIPINEHYDROCHLORIDE(FORR&DONLY)
Lercanidipine hydrochloride heMihydrate
CARD-containing molecule enhancing NF-κ-B
Lercanidipine hemihydrate hydrochloride
1,4-dihydro-2,6-diMethyl-4-(3-nitrophenyl)-3,5-
1,4-Dihydro-2,6-dimethyl-4-(3-nittrophenyl)-3,5-pyridinedicarboxylicAcid2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimeth
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride
O3-[1-[3,3-diphenylpropyl(methyl)amino]-2-methyl-propan-2-yl] O5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
1,4-Dihydro-2,6-dimethyl-4-(3-nittrophenyl)-3,5-pyridinedicarboxylic Acid 2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimethylethyl Methyl Ester Hydrochloride
3-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 5-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
3,5-Pyridinedicarboxylicacid, 1,4-dihydro-2,6-diMethyl-4-(3-nitrophenyl)-,3-[2-[(3,3-diphenylpropyl)MethylaMino]-1,1-diMethylethyl] 5-Methyl ester,hydrochloride (1:1)
2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O3-[2-[3,3-diphenylpropyl(methyl)amino]-1,1-dimethyl-ethyl] ester O5-methyl ester hydrochloride | [EINECS(EC#)]
603-682-3 | [Molecular Formula]
C36H42ClN3O6 | [MDL Number]
MFCD07773089 | [Molecular Weight]
648.19 | [MOL File]
132866-11-6.mol |
| Chemical Properties | Back Directory | [Appearance]
Pale-Yellow Powder | [Melting point ]
175-177°C | [storage temp. ]
2-8°C | [solubility ]
soluble in Methanol | [form ]
powder | [color ]
yellow | [Usage]
A dihydropyridine calcium channel blocker | [Merck ]
14,5446 | [InChIKey]
WMFYOYKPJLRMJI-UHFFFAOYSA-N | [SMILES]
C1(C)NC(C)=C(C(OC(C)(C)CN(CCC(C2=CC=CC=C2)C2=CC=CC=C2)C)=O)C(C2=CC=CC([N+]([O-])=O)=C2)C=1C(OC)=O.[H]Cl | [CAS DataBase Reference]
132866-11-6(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
R25:Toxic if swallowed. | [Safety Statements ]
S36/37:Wear suitable protective clothing and gloves .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [RIDADR ]
UN 2811 | [WGK Germany ]
3 | [HS Code ]
2933.39.4100 | [Toxicity]
LD50 in mice (mg/kg): 83 i.p.; 657 orally (Nardi) |
| Hazard Information | Back Directory | [Chemical Properties]
Pale-Yellow Powder | [Uses]
A dihydropyridine calcium channel blocker. Antihypertensive. | [Uses]
long-acting dihydropyridine calcium channel blocker, antihypertensive | [Definition]
ChEBI:Lercanidipine hydrochloride is a diarylmethane. | [Brand name]
Cardiovasc (Recor dati, Italy); Carmen (Recordati, Italy); Corifeo (Recordati,
Italy); Lercadip (Recordati, Italy); Lercan (Recordati,
Italy); Lercapin (Recordati, Italy); Lercaton (Recordati,
Italy); Lerkamen (Recordati, Italy); Lerzam (Recordati,
Italy); Renovia (Recordati, Italy); Vasodip (Recordati,
Italy); Zandip (Recordati, Italy); Zanicor (Recordati, Italy). | [Biological Activity]
L-type Ca 2+ channel blocker that displays higher vascular selectivity than Felodipine (4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester ). Causes peripheral vasodilation with only weak negative inotropic activity. Antihypertensive. | [Biochem/physiol Actions]
Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine. | [Clinical Use]
#N/A | [Synthesis]
The general procedure for the synthesis of 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl)5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride from the compound (CAS:957215-03-1) is as follows: 10 mmol of oxalate salt (Example 4) was dissolved in 100 mL of dichloromethane and 20 mL of aqueous solution containing 20 mmol of potassium carbonate was added. The organic phase was separated and the aqueous phase was extracted with 2 x 10 mL of dichloromethane. The organic phase was combined and treated with 20 mL of 1N hydrochloric acid solution. The organic phase was separated and concentrated. The residue was dissolved in 2,000 mL of water and 2 mL of 1N hydrochloric acid and 5 mL of saturated aqueous sodium chloride were added to form I hydrochloride hemihydrate and the product was collected by filtration. Yield: 6.2 g (95%); Purity: 99.8% (HPLC); Melting point: 118-122 ° C. HPLC conditions: RP 16 column, 125×3 mm ID, 5 μm, Detection wavelength: 233 nm; Eluent composition: 0.01 mol Na2HPO4/MeOH/acetonitrile=25/65/10; Retention time: about 15 min. | [Drug interactions]
Potentially hazardous interactions with other drugs
Aminophylline and theophylline: possibly increased
aminophylline and theophylline concentration.
Anaesthetics: enhanced hypotensive effect.
Antibacterials: metabolism possibly inhibited by
clarithromycin, erythromycin and telithromycin -
avoid with erythromycin.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antiepileptics: effect reduced by carbamazepine,
barbiturates, phenytoin and primidone.
Antifungals: metabolism possibly inhibited by
itraconazole and ketoconazole - avoid; negative
inotropic effect possibly increased with itraconazole.
Antihypertensives: enhanced hypotensive effect,
increased risk of first dose hypotensive effect of postsynaptic alpha-blockers.
Antivirals: concentration increased by ritonavir -
avoid.
Cardiac glycosides: digoxin concentration increased.
Ciclosporin: concentration of both drugs may be
increased - avoid.
Grapefruit juice: concentration increased - avoid | [storage]
Store at -20°C | [References]
[1] Patent: EP1860102, 2007, A1. Location in patent: Page/Page column 1; 8; 15 |
|
|